Trial · NCT07387848
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
NCT07387848, Phase 2, Recruiting, American University of Beirut Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas. Trials, record NCT07387848. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07387848
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
- NCT number
- NCT07387848
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- American University of Beirut Medical Center
- Conditions
- Diffuse Large B Cell Lymphoma Refractory
- Interventions
- Glofitamab
- First posted
- 2026-02-04
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the efficacy of glofitamab when used as a bridge to and/or consolidation post-transplant for patients with relapsed/refractory B-cell lymphomas (DLBCL or transformed low grade B cell lymphoma) fit and eligible for ASCT | 3 years | Progression free survival (PFS) at 1 year post relapse-defined as the time from infusion of first salvage chemotherapy to the first occurrence of disease progression or death from any cause, whichever occurs first as determined by the investigator |
| Secondary | To evaluate the 3 years overall survival | 3 years | Overall survival (OS) at 3 year post relapse defined as the time from first dose of salvage chemotherapy to date of death from any cause |
| Secondary | To evaluate the safety and tolerability of glofitamab in this setting | 3 years | Incidence and severity of adverse events (AEs), with severity determined according to the national Cancer Institute Common Toxicity Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) |
| Secondary | To evaluate the effect of glofitamab when used as a bridge to and/or consolidation post ASCT on health-related quality of life (HRQoL) | 3 years | Changes in QLQ-NHL-HG29 questionnaire results taken before first dose of glofitamab and that taken at end of treatment with glofitamab. he EORTC QLQ-NHL-HG29 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Non-Hodgkin Lymphoma-High-Grade 29) is a disease-specific quality-of-life instrument. Scores are transformed to a 0-100 scale. For functional domains, higher scores indicate better outcomes, whereas for symptom domains, higher scores indicate worse outcomes. |
| Secondary | To evaluate the effect of treatment with glofitamab on acute phase reactants such as fibrinogen and its clinical significance | 1 year | Changes in fibrinogen level from baseline (before starting first dose of glofitamab compared to post each dose of glofitamab and post last dose of glofitamab) will be correlated with PFS and CRS. |
| Secondary | To Assess the complete response rate | 1 year | the complete response (CR) defined as the proportion of patients whose best overall response is CR on positron emission tomography (PET/CT scan) at two time points (at transplant for those receiving glofitamab as a bridge to ASCT, and at end of treatment (EOT) with glofitamab (3-4 weeks after last dose of post-ASCT consolidation with glofitamab) for all patients |
| Secondary | To Assess the rate of ASCT | 1 year | the rate of ASCT is assessed after induction chemotherapy and after 3 doses of Glofitamab for non- responders. Rate of ASCT for those receiving Glofitamab as salvage therapy is assessed post induction chemo and post 3 dose Glofitamab for non resposnders. |
| Secondary | clinical complete response rate | 6 months | Rate of complete response (CR) defined as the proportion of patients whose best overall response is CR on positron emission tomography (PET/CT scan) at two time points (at transplant for those receiving glofitamab as a bridge to ASCT, and at end of treatment (EOT) with glofitamab (3-4 weeks after last dose of post-ASCT consolidation with glofitamab) for all patients |
| Secondary | Rate of ASCT for patients receiving glofitamab as salvage therapy | 6 months | The rate of autologous stem cells transplantation of patients who received salvage Glofitamab is defined as the proportion of patients who reached the ASCT after completing the salvage Glofitamab treatment after being evaluated by PET scan and Bone Marrow aspirate and biopsy to confirm complete response rate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07387848
GET https://conductscience.org/api/trials/v1/NCT07387848/registered